MOTS-c Legal Status, FDA 503A Category, and Compounding Access

In plain English

Here is the MOTS-c legal status in plain terms. MOTS-c is not an approved medicine. In the United States, pharmacies can sometimes custom-make ("compound") a drug from a raw ingredient, but only if that ingredient clears a specific set of FDA rules. MOTS-c has not cleared them yet — it is on a list of substances the FDA is still reviewing. There is real momentum: MOTS-c is named on the agenda of an FDA advisory-committee meeting set for July 2026 to discuss whether it could be added to the approved-for-compounding list. That is a scheduled discussion, not a decision. Nothing has changed status.

The Current Status, Stated Plainly

MOTS-c — a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region — is a research peptide and is not an FDA-approved drug for any indication. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list; substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) ^[16].

MOTS-c is one of the bulk drug substances FDA has scheduled for PCAC evaluation ^[18]. Being under evaluation is not the same as being on the bulks list or approved for compounding. The peptide's present-tense status is exactly that: a research peptide, not FDA-approved, scheduled for PCAC evaluation. This page does not assign MOTS-c a numbered 503A category, because FDA's audited record covered here does not place MOTS-c in one — and borrowing another substance's category would misstate the facts.

Access Is Under Active FDA Review — and May Expand in 2026

The forward-looking fact is real and anchored: MOTS-c is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[18]. FDA's calendar evaluates it in both free base and acetate forms, and the same agenda also lists BPC-157, TB-500, and KPV ^[18].

That is the momentum — and the limit of it. A PCAC meeting is a scheduled evaluation and discussion only. It is not a listing decision, not a reclassification, and not a change in current status ^[18]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC; being discussed by the committee is a step in evaluation, not a final listing ^[16]. The outcome of the July 2026 meeting is unknown and is not assumed, stated, or dated here. So the honest reading is forward-leaning but hedged: access could expand, the question is on FDA's calendar, and as of today nothing has changed.

How 503A and 503B Compounding Work

Two sections of the Federal Food, Drug, and Cosmetic Act govern compounding ^[16]. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies, federal facilities, and licensed physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers registered "outsourcing facilities" that may compound larger batches under cGMP-style oversight and FDA registration and inspection ^[16].

The gating rule is about the ingredient. A compounder may use a bulk drug substance — an active ingredient used as a starting material rather than an FDA-approved finished drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[16]. Substances not yet on a bulks list are nominated and evaluated by FDA, with PCAC input ^[16]. FDA approval of a finished drug is a separate question from whether a bulk substance may be used in compounding; MOTS-c is not an FDA-approved drug ^[16][18].

How Legally Compounded Peptide Access Works in General

A legally compounded medication in the U.S. is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is clinically appropriate and issues a valid, patient-specific prescription ^[17]. The preparation is then made either by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger volumes, by an FDA-registered 503B outsourcing facility ^[17].

Telehealth can serve as the front-end channel through which a patient is evaluated and a prescription is issued, but it does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate prescriber–patient relationship and a valid prescription ^[17]. Critically, the compounder may use a requested ingredient only if that ingredient is eligible under the 503A/503B rules; a substance FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[17]. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. This site names no pharmacy, clinic, telehealth provider, or vendor, and provides no dosing or protocols.

MOTS-c and Anti-Doping (WADA/USADA) Status

MOTS-c and Anti-Doping (WADA/USADA) Status

MOTS-c is treated as a prohibited substance in elite sport. Anti-doping bodies such as USADA and WADA classify it among peptide and metabolic-modulator agents prohibited at all times, and athlete use can result in sanctions. This standing is independent of the FDA compounding question and applies regardless of how the July 2026 PCAC evaluation proceeds. Athletes subject to anti-doping rules should treat MOTS-c as prohibited.

How MOTS-c Is Sold and Accessed Today

How MOTS-c Is Sold and Accessed

MOTS-c is sold only as a research chemical for laboratory use, not as an approved human medicine or dietary supplement. This site is a research digest: it does not sell MOTS-c and does not recommend any supplier. Material sold for laboratory research is not regulated to pharmaceutical identity, purity, or sterility standards, and those attributes vary by supplier.

Is MOTS-c Available Over the Counter?

No. MOTS-c is not an approved drug or a dietary supplement; it is sold only as a research chemical for laboratory use. There is no over-the-counter or approved human product, and there is no approved indication, formulation, or dosing for it.